The present invention is directed to selective LXR modulators, small molecule compounds corresponding to Formula I and is further directed to a process of treating a condition in a mammal that is modulated by LXR using a therapeutically effective dose of a compound of Formula I.
[EN] ANILINO LIVER X-RECEPTOR MODULATORS<br/>[FR] MODULATEURS DES RECEPTEURS X DU FOIE A STRUCTURE ANILINO
申请人:PHARMACIA CORP
公开号:WO2003099769A1
公开(公告)日:2003-12-04
The present invention is directed to selective LXR modulators, small molecule compounds corresponding to Formula I and is further directed to a process of treating a condition in a mammal that is modulated by LXR using a therapeutically effective dose of a compound of Formula I.